An honest answer about her sons would mean talking about all the things Duchenne MD has taken from them, writes columnist.
A clinical trial testing Duchenne gene-editing therapy candidate PBGENE-DMD will soon launch in the U.S., having won ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...
The Pegg family set up ‘George’s Journey’ family fund with Muscular Dystrophy UK in 2015, inspired by their son George, who ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Accelerated approval can serve patients well—but only when surrogate endpoints are reliable and clearly predict outcomes that matter to patients.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) ...
Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.
A milestone in the treatment of Duchenne muscular dystrophy (DMD) passed recently with remarkably little public notice. That ...
A Fond du Lac woman faces a felony charge after authorities say her 12-year-old son, who had Duchenne muscular dystrophy, ...
Newsworthy Women on MSN
'Didn't feed him': Mom faces charges in 12-year-old's death
Mom Claims 12-Year-Old Boy Rapidly Lost Weight Because of Terminal Illness; Prosecutors Say She Didn’t Feed Him ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results